Repligen CorpRGEN

NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Price (close)
$190.65
Market cap
$10.8B
P/E
259.0x
Revenue (TTM)
$785.1M
Net income
$41.5M
Dividend yield
—
1-year total return
56.7%
Net margin
5.3%
Revenue growth
16.5%
Debt / equity
0.26x

What Repligen Corp does.

No business description on file yet.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$366.3M$670.5M$801.5M$632.4M$634.4M$738.3M
Net income$59.9M$128.3M$186.0M$35.6M-$25.5M$48.9M
Free cash flow$40.2M$51.9M$87.2M$77.7M$149.7M$93.9M

More on RGEN.

Figures from Repligen Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.